Chlorthalidone Compared to Hydrochlorothiazide on Endothelial Function
NCT ID: NCT01822860
Last Updated: 2015-03-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE4
INTERVENTIONAL
2013-03-31
2015-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Antihypertensive Drug Treatment on Brain Blood Flow, Cognition, and Regulation of Nervous System in Older Adults With Hypertension.
NCT06287580
The Effect of Sodium Nitrite on Renal Function and Blood Pressure in Hypertensive Versus Healthy Subjects
NCT02527837
Hypertension Screening and Treatment Program
NCT00007592
Effects of Thiazide Diuretics on Sympathetic Nervous System in Hypertension
NCT00353652
Resistant Arterial Hypertension Cohort Study
NCT01083017
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Chlorthalidone 12.5 mg
Subjects will receive chlorthalidone, hydrochlorothiazide, and placebo each for 4 weeks in a randomized sequence.
Chlorthalidone 12.5 mg
Hydrochlorothiazide 25 mg
Subjects will receive chlorthalidone, hydrochlorothiazide, and placebo each for 4 weeks in a randomized sequence.
Hydrochlorothiazide 25 mg
Placebo
Subjects will receive chlorthalidone, hydrochlorothiazide, and placebo each for 4 weeks in a randomized sequence.
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Chlorthalidone 12.5 mg
Hydrochlorothiazide 25 mg
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of hypertension
* Current blood pressure \> 120/80 mm Hg
Exclusion Criteria
* Known allergy to any study medications
* History of gout or hyperuricemia
* SCr \>/= 1.8 mg/dl or CrCl \< 25 ml/min
* Pregnancy or breastfeeding or planning to become pregnant during study period
* Dementia or cognitive impairment
* Hypokalemia
* Acute coronary syndrome or stroke within 6 months
* Current use of sildenafil, tadalafil, or vardenafil
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Creighton University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ahmed Aboeata, MBBCh
Role: PRINCIPAL_INVESTIGATOR
Creighton University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Creighton University
Omaha, Nebraska, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
13-16628
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.